Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07410598

Safety and Tolerability of Patterned Stimulation for DBS in the Home Setting

The primary objective of the proposed pilot study is to assess the safety and tolerability of active patterned Deep Brain Stimulation (pDBS) when administered in a home setting for patients with Parkinson's disease (PD) who have had stable bilateral Subthalamic Nucleus (STN) and Globus Pallidus internus (GPi) DBS.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Florida

Gainesville, Florida, 32608, United States

Location status: Recruiting

Location contact

Joshua Wong, MD

CONTACT

[email protected]

352-294-5400

About this study

This pilot study will investigate the safety, tolerability, and feasibility of three distinct patterned Deep Brain Stimulation (pDBS) paradigms delivered in a home setting using the Boston Scientific Chronos Research Engine. The three stimulation patterns under evaluation are:

  • Biphasic DBS (bDBS)
  • Nocturnal Theta Burst Stimulation (tDBS)
  • Region-Specific Frequency Alternation (fDBS).

Sixty patients with Parkinson's Disease (PD), each with stable bilateral Subthalamic Nucleus (STN) and Globus Pallidus internus (GPi) DBS for at least six months, will be enrolled and assigned to one of the three parallel study arms. At the baseline visit, each participant will be programmed with two stimulation settings: one replicating their chronic best clinical setting, and a second incorporating the assigned patterned stimulation.

For participants in the bDBS arm, the second setting will mirror their clinical setting but use a biphasic waveform to ensure charge balancing. In the tDBS arm, the second setting will deliver theta burst stimulation-six bursts per second at the therapeutic frequency-during nighttime hours, using the internal IPG clock to align with the participant's typical sleep schedule. For those in the fDBS arm, the second setting will apply high-frequency stimulation to dorsal contacts (Levels 3 or 4) and low-frequency stimulation (30-60 Hz) to ventral contacts (Levels 1 or 2), while maintaining all other clinical parameters.

Participants will be blinded to the identity of the two settings and will be able to switch between them using their patient programmer. The study will follow a randomized, blinded, two-period crossover design over a total duration of four weeks. During the first two weeks, participants will use one of the two programmed settings. At the end of this period, a telemedicine visit will be conducted to collect quality of life (QoL) questionnaires, related surveys, and a video-based modified MDS-UPDRS assessment. Participants will then switch to the alternate setting for the remaining two weeks. At the conclusion of the study, participants will return for an in-person research visit to complete the same assessments for the second setting. This design allows for within-subject comparison of conventional DBS and patterned DBS in a real-world, home-based environment, and will generate critical data to inform the design of a future large-scale trial.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Bilateral STN or GPi DBS with Boston Scientific Vercise Genus DBS System
  • Diagnosis of Parkinson's disease as confirmed by a movement disorders fellowship trained neurologist
  • Chronic stable DBS therapy, defined as having DBS therapy for at least 6 months

Exclusion criteria

  • History of previous neurosurgical intervention aside from DBS
  • Diagnosis of dementia (whether primary or related to Parkinson's disease)
  • A diagnosis of atypical parkinsonism or secondary parkinsonism at any time after DBS implantation

Treatment and study plan

Biphasic deep brain stimulation

Device

Deep brain stimulation using active recharge biphasic waveforms consisting of an equal anodic and cathodic pulse immediately delivered sequentially

conventional deep brain stimulation

Device

Conventional deep brain stimulation programming that is currently FDA approved

Theta burst deep brain stimulation

Device

Deep brain stimulation using a conventional waveform but timed such that in the evening hours (based on device clock) the device will adjust stimulation to bursts of conventional stimulation at 6 per second

Multi frequency deep brain stimulation

Device

Deep brain stimulation using conventional waveforms but simultaneously delivering high frequency stimulation on the dorsal contacts of the DBS lead and low frequency stimulation on the ventral contacts of the DBS lead

Primary outcomes

  1. Tolerability of patterned DBS

    Time frame: From enrollment to the end of novel waveform trial period at 2 weeks

    The primary endpoint of this study is the proportion of participants who are able to tolerate patterned DBS (pDBS) for the full two-week intervention period. Tolerability is defined as the ability to remain on the assigned pDBS setting without reverting to an alternative DBS configuration.

Secondary outcomes

  1. Change in motor symptom severity

    Time frame: From enrollment to the end of study period at 4 weeks

    A comparison of the modified MDS-UPDRS between conventional and patterned waveform based on a video assessment

  2. Change in quality of life

    Time frame: From enrollment to the end of the study period at 4 weeks

    A comparison of quality of life metrics through the Parkinson's Disease Questionnaire (PDQ-39) between conventional and patterned DBS

Study contacts

Contact information is provided by the study sponsor or research team.

Joshua Wong, MD

CONTACT

[email protected]

352-294-5400

Sponsors and collaborators

Lead sponsor

University of Florida

Other

Collaborators

  • Boston Scientific Corporation

Registry information

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Feb 13, 2026
Registry last updated
Jul 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.